Synergy Pharmaceuticals Inc - Strategic SWOT Analysis Review

December 2019 | 37 pages | ID: S86615B4B2D6EN
GlobalData

Abstracts

Synergy Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.

Synergy Pharmaceuticals Inc Key Recent Developments

Mar 01,2019: Synergy Pharmaceuticals receives court approval for the sale of its assets to Bausch Health
Jan 08,2019: Sure Med Compliance partners with Synergy Laboratories to advance the fight against opioid abuse
Dec 14,2018: Bausch Health makes $200m bid for bankrupt Synergy Pharmaceuticals
Nov 08,2018: Synergy Pharmaceuticals reports third quarter 2018 financial results and business update
Oct 31,2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Synergy Pharmaceuticals Inc - Key Facts
Synergy Pharmaceuticals Inc - Key Employees
Synergy Pharmaceuticals Inc - Key Employee Biographies
Synergy Pharmaceuticals Inc - Major Products and Services
Synergy Pharmaceuticals Inc - History
Synergy Pharmaceuticals Inc - Company Statement
Synergy Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Synergy Pharmaceuticals Inc - Business Description
R&D Overview
Synergy Pharmaceuticals Inc - Corporate Strategy
Synergy Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Synergy Pharmaceuticals Inc - Strengths
Synergy Pharmaceuticals Inc - Weaknesses
Synergy Pharmaceuticals Inc - Opportunities
Synergy Pharmaceuticals Inc - Threats
Synergy Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Mar 01, 2019: Synergy Pharmaceuticals receives court approval for the sale of its assets to Bausch Health
Jan 08, 2019: Sure Med Compliance partners with Synergy Laboratories to advance the fight against opioid abuse
Dec 14, 2018: Bausch Health makes $200m bid for bankrupt Synergy Pharmaceuticals
Nov 08, 2018: Synergy Pharmaceuticals reports third quarter 2018 financial results and business update
Oct 31, 2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman
Aug 07, 2018: Synergy Pharmaceuticals reports second quarter 2018 financial results and business update
May 10, 2018: Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update
Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Synergy Pharmaceuticals Inc, Key Facts
Synergy Pharmaceuticals Inc, Key Employees
Synergy Pharmaceuticals Inc, Key Employee Biographies
Synergy Pharmaceuticals Inc, Major Products and Services
Synergy Pharmaceuticals Inc, History
Synergy Pharmaceuticals Inc, Subsidiaries
Synergy Pharmaceuticals Inc, Key Competitors
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

AstraZeneca Plc
Takeda Pharmaceuticals America Inc
Shire Ltd
Ironwood Pharmaceuticals Inc
Allergan Plc
Sucampo Pharmaceuticals Inc
Ocera Therapeutics Inc
Bausch Health Companies Inc